We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies
Read MoreHide Full Article
Key Takeaways
Pfizer signs a $2.6 billion deal for three CAR-T programs targeting autoimmune diseases.
The deal includes $330 million upfront and up to $2.3 billion in milestone payments.
Pfizer gains ex-China rights to develop, manufacture and commercialize the three programs.
Pfizer (PFE - Free Report) announced that it has entered into an exclusive licensing deal with China-based Starna Therapeutics for the latter’s three investigational chimeric antigen receptor T-cell (CAR-T) programs targeting autoimmune diseases.
Under the agreement, Starna Therapeutics will receive an upfront payment of $330 million. In addition, PFE will pay up to $2.3 billion in potential milestone payments, along with royalties on net sales of any approved products under the deal.
What Pfizer Gets Out of the Deal
PFE will obtain exclusive rights outside Greater China to develop, manufacture and commercialize three preclinical in vivo CAR-T programs. The company will lead clinical development in these territories and plans to manufacture the finished drug products for initial clinical studies at its U.S. facilities
In addition, Pfizer will receive rights to use Starna's proprietary in vivo CAR-T technology in inflammation, immunology and oncology. It will also hold options to exclusively license compounds developed under a separate research collaboration.
The company will also have the option to expand its licensing territory to include Greater China.
PFE Stock Performance
Year to date, the company’s shares have gained nearly 13% compared with the industry’s 21% growth.
Image Source: Zacks Investment Research
PFE Explores Next-Generation CAR-T Therapies
Unlike conventional CAR-T therapies, which involve collecting T cells from patients, genetically modifying and multiplying them in a laboratory before reinfusing them into the body, in vivo CAR-T therapies aim to genetically modify T cells directly inside the patient's body. This approach eliminates the need for extracting and processing cells outside the body, potentially reducing manufacturing complexities, treatment timelines and costs.
Through the deal with Starna, Pfizer is looking to capitalize on this emerging technology to develop next-generation treatments for autoimmune diseases.
PFE's move follows similar efforts by other large-cap drugmakers to strengthen their presence in the in vivo CAR-T space through strategic deals. AbbVie (ABBV - Free Report) acquired Capstan Therapeutics in 2025, gaining access to its lead in vivo CAR-T candidate, CPTX2309, which is being evaluated in a phase I study for autoimmune diseases.
Similarly, Eli Lilly (LLY - Free Report) acquired Orna Therapeutics earlier this year, adding its in vivo CAR-T platform and lead candidate, ORN-252, targeting B-cell-driven autoimmune diseases.
Image: Bigstock
PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies
Key Takeaways
Pfizer (PFE - Free Report) announced that it has entered into an exclusive licensing deal with China-based Starna Therapeutics for the latter’s three investigational chimeric antigen receptor T-cell (CAR-T) programs targeting autoimmune diseases.
Under the agreement, Starna Therapeutics will receive an upfront payment of $330 million. In addition, PFE will pay up to $2.3 billion in potential milestone payments, along with royalties on net sales of any approved products under the deal.
What Pfizer Gets Out of the Deal
PFE will obtain exclusive rights outside Greater China to develop, manufacture and commercialize three preclinical in vivo CAR-T programs. The company will lead clinical development in these territories and plans to manufacture the finished drug products for initial clinical studies at its U.S. facilities
In addition, Pfizer will receive rights to use Starna's proprietary in vivo CAR-T technology in inflammation, immunology and oncology. It will also hold options to exclusively license compounds developed under a separate research collaboration.
The company will also have the option to expand its licensing territory to include Greater China.
PFE Stock Performance
Year to date, the company’s shares have gained nearly 13% compared with the industry’s 21% growth.
Image Source: Zacks Investment Research
PFE Explores Next-Generation CAR-T Therapies
Unlike conventional CAR-T therapies, which involve collecting T cells from patients, genetically modifying and multiplying them in a laboratory before reinfusing them into the body, in vivo CAR-T therapies aim to genetically modify T cells directly inside the patient's body. This approach eliminates the need for extracting and processing cells outside the body, potentially reducing manufacturing complexities, treatment timelines and costs.
Through the deal with Starna, Pfizer is looking to capitalize on this emerging technology to develop next-generation treatments for autoimmune diseases.
PFE's move follows similar efforts by other large-cap drugmakers to strengthen their presence in the in vivo CAR-T space through strategic deals. AbbVie (ABBV - Free Report) acquired Capstan Therapeutics in 2025, gaining access to its lead in vivo CAR-T candidate, CPTX2309, which is being evaluated in a phase I study for autoimmune diseases.
Similarly, Eli Lilly (LLY - Free Report) acquired Orna Therapeutics earlier this year, adding its in vivo CAR-T platform and lead candidate, ORN-252, targeting B-cell-driven autoimmune diseases.
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
PFE’s Zacks Ranks
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.